255 related articles for article (PubMed ID: 25145430)
41. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
42. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
[TBL] [Abstract][Full Text] [Related]
43. Darbepoetin alpha coming of age.
Pedrazzoli P; Cinieri S; Lorusso V; Gamucci T; Secondino S; Silvestris N
Anticancer Res; 2007; 27(6C):4419-24. PubMed ID: 18214054
[TBL] [Abstract][Full Text] [Related]
44. Clinical and economic evaluation of an evidence-based institutional epoetin-utilization management program.
Buckley MS; Kane-Gill SL; Patel SA
Clin Ther; 2013 Mar; 35(3):294-302. PubMed ID: 23465799
[TBL] [Abstract][Full Text] [Related]
45. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Chan A; Lim LL; Tao M
Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
[TBL] [Abstract][Full Text] [Related]
46. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy: an open-label, non randomized, pilot study.
Santini D; Vincenzi B; La Cesa A; Virzi V; Navajas F; Malafarina V; Dicuonzo G; Cassandro R; Esposito V; Montesarchio V; Groeger AM; Tonini G
Anticancer Res; 2005; 25(1B):669-74. PubMed ID: 15816644
[TBL] [Abstract][Full Text] [Related]
47. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
Killian AD; Gupta V; Goetz AE
Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
[TBL] [Abstract][Full Text] [Related]
48. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia.
Shord SS; Hamilton JM; Cuellar S
J Oncol Pharm Pract; 2008 Mar; 14(1):5-22. PubMed ID: 18337436
[TBL] [Abstract][Full Text] [Related]
49. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
Sanz-Granda A
Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
[TBL] [Abstract][Full Text] [Related]
50. Impact of epoetin alfa in chemotherapy-associated anemia.
Jilani SM; Glaspy JA
Semin Oncol; 1998 Oct; 25(5):571-6. PubMed ID: 9783596
[TBL] [Abstract][Full Text] [Related]
51. Darbepoetin alfa: potential role in managing anemia in cancer patients.
Pirker R; Smith R
Expert Rev Anticancer Ther; 2002 Aug; 2(4):377-84. PubMed ID: 12647980
[TBL] [Abstract][Full Text] [Related]
52. Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer.
McBride A; MacDonald K; Fuentes-Alburo A; Abraham I
J Med Econ; 2021; 24(1):743-756. PubMed ID: 34003067
[TBL] [Abstract][Full Text] [Related]
53. Questionable conclusions about epoetin alfa.
Kruse MW; Lee JJ
Am J Health Syst Pharm; 2007 Sep; 64(17):1789-90; author reply 1790-1. PubMed ID: 17724355
[No Abstract] [Full Text] [Related]
54. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
Lynch DM; Slaven T
Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
[No Abstract] [Full Text] [Related]
55. HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours.
Weigang-Köhler K; Vetter A; Thyroff-Friesinger U
Onkologie; 2009 Apr; 32(4):168-74. PubMed ID: 19372711
[TBL] [Abstract][Full Text] [Related]
56. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
57. Darbepoetin alfa therapeutic interchange protocol for anemia in dialysis.
Brophy DF; Ripley EB; Kockler DR; Lee S; Proeschel LA
Ann Pharmacother; 2005 Nov; 39(11):1808-11. PubMed ID: 16189281
[TBL] [Abstract][Full Text] [Related]
58. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
59. Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series.
Muñoz Ramos P; Gil Giraldo Y; Álvarez Chiva V; Quiroga B
Medwave; 2021 Oct; 21(9):e8474. PubMed ID: 34669690
[TBL] [Abstract][Full Text] [Related]
60. Management of chemotherapy-induced anemia in solid tumors.
Thatcher N
Semin Oncol; 1998 Jun; 25(3 Suppl 7):23-6. PubMed ID: 9671326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
